Novartis' Kisqali CHMP Nod In Fast-Moving Market
The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer marketing battle that is likely to get more intense.
You may also be interested in...
CDK4/6 inhibitors offer impressive progression-free survival data in breast cancer, but lack of overall survival data may mean the class will be relegated to the second-line setting.
NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.